Alloy Therapeutics

Also offer services for antibody discovery and development

Alloy Therapeutics describes itself as a biotechnology ecosystem company that enables pre-competitive drug discovery at all levels. Alloy currently offers licensing in antibody and TCR platforms, drug discovery and optimization services, and subscription-based access to pre-competitive technology. Alloy utilizes highly immunocompetent transgenic mice to produce maximum diversity and epitopic coverage with their ATX-Gx antibody platform. They also offer their ATX-CLC platform for common-light chain bispecific and multispecific discovery as well as their ATX-SiD platform for the discovery of single-domain antibodies. The Keyway TCR Discovery Services offer access to custom therapeutic TCR mimics and engineered TCRs against custom targets.